Roy Perlis is an associate member of the Broad Institute, active in the Stanley Center for Psychiatric Research. He focuses both his research and clinical work on treatment-resistant mood disorders, including bipolar disorder and major depressive disorder. His current efforts include exploring genetic variations that might predict treatment response or adverse effects, conducting proof-of-concept clinical trials with new treatments, and developing cost-effective methods for future genetics research using algorithms to search medical record databases.
Perlis earned a B.Sc. in neuroscience from Brown University, an M.D. from Harvard Medical School, and an M.Sc. in biostatistics from the Harvard School of Public Health. He completed residency and chief residency at Massachusetts General Hospital (MGH) and McLean Hospital, and completed a clinical/research fellowship at MGH before joining the faculty. He created the laboratory of psychiatric pharmacogenomics and subsequently served as medical director of the MGH Bipolar Disorder Clinic and Research Program, one of the world’s largest such clinics. In 2011 he launched the Center for Experimental Drugs and Diagnostics, at MGH, in an effort to speed the translation of bench science to clinical applications.